ハギワラ　ノブヒサ   Nobuhisa Hagiwara   萩原　誠久    所属   その他 その他    職種   非常勤嘱託
言語種別	英語
発表タイトル	Under-diagnosis and Under-treatment of Heterozygous Familial Hypercholesterelaemia in Patients with Cardiovascular Diseases
会議名	ESC CONGRESS 2017
主催者	European Society of Cardiology
学会区分	国際学会及び海外の学会
発表形式	ポスター掲示
講演区分	一般
発表者・共同発表者	SEKIGUCHI Haruki, IIDA Tatsuro, KANBAYASHI Keigo, TAKANO Mayu, ◎SAKAI Akiko, SATO Kayoko, HAGIWARA Nobuhisa
発表年月日	2017/08/29
開催地 （都市, 国名）	Barcelona, SPAIN
学会抄録	European Heart Journal 38(suppl_1),6498 2017
概要	Background: Heterozygous familial hypercholesterolaemia (hFH) is most common genetic disease and cause of premature cardiovascular disease (CVD). However, the diagnosis rate is less than 0.1% in Japan. Purpose: We examined the patients hospitalized for CVD and evaluate the extent to which hFH is underdiagnosed and undertreated. Methods: We analyzed the consecutive 553 patients hospitalized for CVD from 2013 to 2015. To investigate the prevalence of hFH, we focused on the patients with high LDL-C levels more than 140mg/dL in these CVD patients. Results: Sixty-four patients had high LDL-C levels. In those, 37 (6.7% of all CVD) patients were diagnosed as hFH (62.9±15.4 years) according to FH guidelines. We compared lipids profiles between hFH and the patients with hypercholesterolemia (DL, 68.3±15.0 years). The hFH patients had significantly higher T-cho levels (243.8±32.3mg/dL, 224.1±15.0mg/dL, P<0.01, respectively) and LDL-C levels (172.5±24.2mg/dL, 152.3±8.2mg/dL, P<0.01, respectively) than DL patients. Blood pressure, EF, TG, HDL-C, Cre, BNP, CRP were not significant difference between hFH and DL. Furthermore, 32.4% of hFH had the past history of CVD. However, just 27% of hFH were treated with statins on admission, and also only 0.05% of hFH had a definitive diagnosis at discharge. Conclusions Owing to severe underdiagnosis and under treatment of hFH, there is an urgent need for diagnostic screening together with early and aggressive treatments of high-risk condition of future cardiovascular events.